About Kristin Muhlner
Form D filings for Affect Therapeutics from 2021 to 2023 list Kristin Muhlner as chief executive officer and director.
Kristin Muhlner first appears on SEC filings in 2021.
Experience
This experience comes from SEC filings. The years are when the filings name Kristin Muhlner in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Kristin Muhlner works with at each company, as listed on that company's latest Form D.
Affect Therapeutics, Inc. · Form D, Jul 12, 2023